Atea Pharmaceuticals, Inc. (AVIR) stock
AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.99+0.03 (+0.76%)
Close on Nov 18, 2026Market cap $320.02MP/E –Yield –
Atea Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Atea Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$183.61M. For fiscal 2025 it was -$180.89M. The highest annual figure on record is $138.38M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$180.89M | – |
| FY2024 | Dec 31, 2024 | -$192.95M | – |
| FY2023 | Dec 31, 2023 | -$164.16M | – |
| FY2022 | Dec 31, 2022 | -$130.65M | -194.4% |
| FY2021 | Dec 31, 2021 | $138.38M | – |
| FY2020 | Dec 31, 2020 | -$11.03M | – |
| FY2019 | Dec 31, 2019 | -$14.61M | – |
| FY2018 | Dec 31, 2018 | -$9.48M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$35.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$48.01M | – |
| Q4 FY2025 | Dec 31, 2025 | -$54.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$45.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.35M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.04M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$46.92M | – |
| Q1 FY2024 | Mar 31, 2024 | -$69.81M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.57M | – |
| Q3 FY2023 | Sep 30, 2023 | -$40.79M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.24M | – |
| Q1 FY2023 | Mar 31, 2023 | -$41.57M | – |
| Q4 FY2022 | Dec 31, 2022 | -$39.90M | -132.9% |
| Q3 FY2022 | Sep 30, 2022 | -$16.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -$32.30M | -471.8% |
| Q1 FY2022 | Mar 31, 2022 | -$42.18M | -237.6% |
| Q4 FY2021 | Dec 31, 2021 | $121.18M | +486.9% |
| Q3 FY2021 | Sep 30, 2021 | -$22.15M | – |
| Q2 FY2021 | Jun 30, 2021 | $8.69M | – |
| Q1 FY2021 | Mar 31, 2021 | $30.66M | – |
| Q4 FY2020 | Dec 31, 2020 | $20.65M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.63M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.05M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.75M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.77M | – |
See a number that looks wrong?